0810010067/J591; A Randomized Phase II Trial of 177-Lu Radio-labeled Monoclonal Antibody HuJ591 (177-Lu-J591) with Ketoconazole in Patients with High-Risk Castrate Biochemically Relapsed Prostate Cancer after Local Therapy

Study Overview

The purpose of this study is to test the effectiveness of the experimental drug, 177Lu-J591 in combination with ketoconazole and hydrocortisone against prostate cancer.

Study Description

This research is being done because the standard treatments for prostate cancer that has returned (PSA is elevated) after surgery and/or radiation and progressed on initial hormonal therapy are not curative. The study will assess the potential of the energy given off by the radioactive compound to kill cancer cell.

Additional Information

Participants will not be paid for their participation.


  • IRB Number: 1011003440 (1004-12)
  • Research Study Identifier: TX717
  • Principal Investigator: Costantine Albany, MD

Recruitment Status

Closed
Volunteer Sign up

Volunteer Registry

Create your profile and be matched to research opportunities

Register Now!

Contact Us

If you need help finding a study or have any questions, please contact us at inhealth@iu.edu or by phone at (888) 264-0005.